Chronic treatment with the tetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic cholinergic and sigma-1 ligand, alleviates pathology in Tg2576 mice, a transgenic Alzheimer’s disease model.
Blockade of Tau Hyperphosphorylation and Ab1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and r1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease.
Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of Alzheimer’s Disease
Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer’s Disease
